Journal: Frontiers in Immunology
Article Title: Aberrant glycosylation patterns as potential biomarkers for diagnosis and disease progression in bullous pemphigoid
doi: 10.3389/fimmu.2025.1538126
Figure Lengend Snippet: Correlation analysis of serum and blister fluid glycosylation with BP clinical indicators, and diagnostic accuracy assessed by ROC analysis. (a) Evaluation of the correlation between 6 glycosylation structures (binding to PHA-L, SNA, PSA, SBA, RCA120, AAL) and clinical indicators (BP180 and BP230 antibody titers, eosinophil count and percentage, white blood cell count, total serum IgE titer, erythrocyte sedimentation rate, high-sensitivity C-reactive protein level, hospital stay duration, age) in serum. (b) Evaluation of the correlation between 6 glycosylation structures (binding to PHA-L, SNA, PSA, SBA, RCA120, AAL) and clinical indicators (BP180 and BP230 antibody titers, eosinophil count and percentage, total protein, albumin, sodium, potassium, calcium ion concentrations, age, and the six glycosylation modifications) in blister fluid. Spearman’s correlation analysis was used for statistical testing. X indicates p>0.05 after statistical testing. Red color represents positive correlation, while blue color represents negative correlation. The larger and deeper the circle, the stronger the correlation coefficient. (c) ROC analysis for serum glycopatterns recognized by lectin PSA, SNA, SBA to discriminate BP patients from healthy controls. (d) ROC analysis for blister fluid glycopatterns recognized by lectin RCA120, SBA, AAL to discriminate BP patients from control group. The area under the curve (AUC) is used as a metric of diagnostic ability.
Article Snippet: Briefly, during Lectin ELISA of serum and blister fluid, biotinylated lectins were diluted with 1% BSA to the following concentrations: HPA-L (Vector, B-1115) 5μg/mL, SNA (Vector, B-1305) 0.5μg/mL, PSA (Vector, B-1055) 0.5μg/mL, SBA (Vector, B-1015) 0.5μg/mL, RCA120 (Vector, B-1085) 0.05μg/mL, AAL (Vector, B-1395) 0.01μg/mL, while during Lectin ELISA of saliva, biotinylated lectins were diluted to the following concentrations: HPA-L 5μg/mL, SNA 2μg/mL, PSA 1μg/mL, SBA 5μg/mL, RCA120 1μg/mL, AAL 1μg/mL.
Techniques: Glycoproteomics, Diagnostic Assay, Binding Assay, Cell Counting, Sedimentation, Control